Considering your high risk NTM population, what are the indications for systemic (IV) amikacin therapy, what are the limiting and concerning side effects, and what are the potential side effect-mitigating properties in patients with MAC lung disease?
Created by
Presenter
Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary